Survodutide (10mg)

Description

Survodutide (BI 456906) is a dual GLP-1 receptor / glucagon receptor co-agonist developed by Boehringer Ingelheim and Zealand Pharma. As a lipid-conjugated peptide with balanced activity at both receptors, it represents the leading research compound for studying the synergistic metabolic effects of simultaneous GLP-1 and glucagon pathway activation — a strategy now recognized as producing superior weight loss and hepatic lipid reduction versus single-receptor agonism.

Why Researchers Select Survodutide

GLP-1 receptor agonism reduces appetite and improves insulin secretion; glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure. Survodutide co-activates both pathways, producing additive effects on body weight reduction and a particularly pronounced reduction in hepatic steatosis — making it highly relevant for NASH/MAFLD research. Phase 2 clinical trial data demonstrate meaningful reductions in liver fat content and body weight, providing a well-characterized reference point for translational metabolic research. In animal models, its glucagon receptor activity also modulates bile acid metabolism and gut microbiome composition.

Common Research Applications

• Dual GLP-1/glucagon receptor co-agonism pharmacology
• NASH/MAFLD hepatic steatosis and lipid reduction research
• Energy expenditure and thermogenesis pathway studies
• Comparative single vs. dual receptor agonism metabolic models
• Bile acid metabolism and gut-liver axis research

Molecular Profile

• Type: Lipid-conjugated dual GLP-1R/GCGR co-agonist peptide
• Aliases: BI 456906 | Purity: ≥98% HPLC

For Research Use Only. Not for human or veterinary use.